Compositions and methods for treating central nervous system (cns) disorders and mood disorders
US-2018319843-A1 · Nov 8, 2018 · US
Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N
US10653743B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10653743-B2 |
| Application number | US-201615768267-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 17, 2016 |
| Priority date | Oct 15, 2015 |
| Publication date | May 19, 2020 |
| Grant date | May 19, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods for treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising compound PG-20N in a pharmaceutically acceptable carrier is described. According to another embodiment, the subject disclosure features method of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment. The method may comprise administering to the subject a therapeutically effective amount of a composition comprising PG-20N.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a depressive disorder or an anxiety disorder in a subject in need of such treatment, said method comprising administering to the subject a therapeutically effective amount of a composition comprising: in a pharmaceutically acceptable carrier. 2. The method of claim 1 , wherein the subject is a mammal. 3. The method of claim 2 , wherein the mammal is a human. 4. The method of claim 1 , wherein the composition is administered in a dosage of about 0.001 mg/kg to 100 mg/kg of body weight. 5. The method of claim 1 , wherein the composition is administered at least once daily, at least once every other day, or at least once weekly. 6. The method of claim 1 , wherein the composition is administered intravenously, transdermally, or orally. 7. A method of treating a depressive disorder in a subject in need of such treatment, said method comprising administering to the subject a therapeutically effective amount of a composition comprising: in a pharmaceutically acceptable carrier, wherein administration of the composition treats the depressive disorder in the subject such that clinical improvement is observed in about 1 to 14 days. 8. The method of claim 7 , wherein the subject is a mammal. 9. The method of claim 8 , wherein the mammal is a human. 10. The method of claim 7 , wherein the composition is administered in a dosage of about 0.001 mg/kg to 100 mg/kg of body weight. 11. The method of claim 7 , wherein the composition is administered at least once daily, at least once every other day, or at least once weekly. 12. The method of claim 7 , wherein the composition is administered intravenously, transdermally, or orally.
Assignees
Inventors
Classifications
having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame · CPC title
- A61K38/08Primary
Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title
having 5 to 11 amino acids · CPC title
G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10653743B2 cover?
- Compositions and methods for treating a depressive disorder or an anxiety disorder in a subject in need of such treatment are described. A therapeutically effective amount of a composition comprising compound PG-20N in a pharmaceutically acceptable carrier is described. According to another embodiment, the subject disclosure features method of treating a depressive disorder or an anxiety disord…
- Who is the assignee on this patent?
- Univ Arizona, Texas A & M Univ Sys
- What technology area does this patent fall under?
- Primary CPC classification A61K38/08. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).